Epoprostenol Sodium

依前列醇钠

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameEpoprostenol Sodium
Drug Alias NameProstacyclin sodium环依前列烯醇epoprostenolum前列环素I2Valetri +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid IP receptor agonistsPlatelet aggregation inhibitors
TargetsProstanoid IP receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Brain Injuries, TraumaticPulmonary Arterial Hypertension +[4] 
Global Approved IndicationsPulmonary Arterial Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1995/09/20
Country/TerritoryBelgiumCanadaUnited States +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesAerogen Pharma Ltd
Inactive CompaniesUniversity Of AlbertaUmeå UniversityGlaxosmithkline Llc +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsBrain Injuries, TraumaticPulmonary Arterial HypertensionHypertension, Pulmonary

Other Information

ATC CodeB01AC09
Related LinksWikipediaDrugBankKEGG